AGM의 결과
렌크 AG
N / A
07:46 20/03/24
11 April 2024 1730 BST
Results of Annual General Meeting held on 11 April 2024
AstraZeneca PLC announced the results of the voting at its Annual General Meeting (AGM) today. As proposed in the Notice of AGM, all Resolutions were decided by poll vote. Resolutions 11 - 14 were passed as special resolutions; all other resolutions were passed as ordinary resolutions.
| 분해능 | 투표 | 투표율 % | 반대 투표 | 투표율 % | 총 투표수 | 발행된 주식 자본금의 %로 표시된 총 의결권 | 보류 된 투표 |
1 | To receive the Company's Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended 31 December 2023 | 1,205,690,871 | 99.88 | 1,470,816 | 0.12 | 1,207,161,687 | 77.87% | 9,700,968 |
2 | To confirm dividends | 1,215,177,590 | 99.94 | 790,189 | 0.06 | 1,215,967,779 | 78.44% | 894,978 |
3 | To reappoint PricewaterhouseCoopers LLP as Auditor | 1,208,377,872 | 99.36 | 7,843,545 | 0.64 | 1,216,221,417 | 78.45% | 642,048 |
4 | To authorise the Directors to agree the remuneration of the Auditor | 1,215,717,786 | 99.98 | 279,816 | 0.02 | 1,215,997,602 | 78.44% | 722,222 |
5a | To re-elect Michel Demaré as a Director | 1,197,325,871 | 98.49 | 18,416,788 | 1.51 | 1,215,742,659 | 78.42% | 1,120,559 |
5b | To re-elect Pascal Soriot as a Director | 1,206,729,787 | 99.26 | 9,036,742 | 0.74 | 1,215,766,529 | 78.42% | 1,098,706 |
5c | To re-elect Aradhana Sarin as a Director | 1,212,225,383 | 99.71 | 3,509,122 | 0.29 | 1,215,734,505 | 78.42% | 1,129,532 |
5d | To re-elect Philip Broadley as a Director | 1,197,937,103 | 98.54 | 17,773,671 | 1.46 | 1,215,710,774 | 78.42% | 1,153,360 |
5e | To re-elect Euan Ashley as a Director | 1,213,332,278 | 99.80 | 2,375,199 | 0.20 | 1,215,707,477 | 78.42% | 1,156,567 |
5f | To re-elect Deborah DiSanzo as a Director | 1,215,396,504 | 99.97 | 318,525 | 0.03 | 1,215,715,029 | 78.42% | 1,149,106 |
5g | To re-elect Diana Layfield as a Director | 1,215,424,019 | 99.98 | 292,514 | 0.02 | 1,215,716,533 | 78.42% | 1,147,602 |
5h | To elect Anna Manz as a Director | 1,215,297,866 | 99.97 | 417,067 | 0.03 | 1,215,714,933 | 78.42% | 1,149,091 |
5i | To re-elect Sheri McCoy as a Director | 1,158,846,767 | 95.32 | 56,874,293 | 4.68 | 1,215,721,060 | 78.42% | 1,142,920 |
5j | To re-elect Tony Mok as a Director | 1,215,346,936 | 99.97 | 346,157 | 0.03 | 1,215,693,093 | 78.42% | 1,170,931 |
5k | To re-elect Nazneen Rahman as a Director | 1,191,449,316 | 98.59 | 16,988,178 | 1.41 | 1,208,437,494 | 77.95% | 8,426,242 |
5l | To re-elect Andreas Rummelt as a Director | 1,215,395,253 | 99.97 | 314,359 | 0.03 | 1,215,709,612 | 78.42% | 1,154,412 |
5m | To re-elect Marcus Wallenberg as a Director | 947,479,100 | 77.93 | 268,252,536 | 22.07 | 1,215,731,636 | 78.42% | 1,132,416 |
6 | 31년 2023월 XNUMX일 종료된 연도의 보수에 관한 연례 보고서 승인 | 1,158,470,360 | 95.32 | 56,835,406 | 4.68 | 1,215,305,766 | 78.40% | 1,558,941 |
7 | 이사 보수 정책 승인
| 761,702,826 | 64.43 | 420,514,520 | 35.57 | 1,182,217,346 | 76.26% | 34,645,873 |
8 | To approve amendments to the AstraZeneca Performance Share Plan 2020
| 769,577,451 | 65.34 | 408,204,003 | 34.66 | 1,177,781,454 | 75.97% | 39,083,170 |
9 | To authorise limited political donations | 1,184,223,861 | 98.00 | 24,219,787 | 2.00 | 1,208,443,648 | 77.95% | 8,278,265 |
10 | 이사가 주식을 할당할 수 있는 권한을 부여하기 위해 | 1,129,625,915 | 92.94 | 85,836,406 | 7.06 | 1,215,462,321 | 78.41% | 1,259,562 |
11 | 이사가 우선매수권을 취소할 수 있는 권한을 부여하기 위해 | 1,044,559,011 | 85.95 | 170,708,848 | 14.05 | 1,215,267,859 | 78.39% | 1,454,048 |
12 | To authorise the Directors to further disapply pre-emption rights for acquisitions and specified capital investments | 997,629,834 | 82.33 | 214,143,713 | 17.67 | 1,211,773,547 | 78.17% | 4,948,031 |
13 | 회사가 자신의 주식을 구매하도록 승인하기 위해 | 1,205,828,976 | 99.23 | 9,306,860 | 0.77 | 1,215,135,836 | 78.38% | 1,585,923 |
14 | 총회 공지기간을 단축하기 위해 | 1,131,157,449 | 93.07 | 84,269,754 | 6.93 | 1,215,427,203 | 78.40% | 1,294,801 |
A copy of the resolutions passed at the AGM (other than resolutions concerning ordinary business) has been submitted to the National Storage Mechanism for publication, and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
Statement in connection with resolutions 5m, 7 and 8
AstraZeneca is pleased that all resolutions were supported at today's Annual General Meeting. In particular, the Board thanks the majority of our shareholders who have supported the Remuneration Policy (the Policy) and will continue to engage with our shareholders and the proxy advisors to explain our need for global benchmarks and pay for performance, which is driven by the Policy.
We will publish an update on the engagement with shareholders on resolutions 5m, 7 and 8 and on any action taken as a result within six months of today's AGM, in accordance with the UK Corporate Governance Code.
발행 자본
As at 9 April 2024, the number of issued shares of the Company was 1,550,231,084 ordinary shares, which was the total number of shares entitling the holders to attend and vote for or against all of the resolutions at the AGM. In accordance with the Company's Articles of Association, on a poll every member present in person or by proxy has one vote for every share held.
아스트라 제네카
AstraZeneca(LSE/STO/Nasdaq: AZN)는 심혈관, 신장 및 대사, 호흡기를 포함한 종양학, 희귀 질환 및 바이오 제약 분야에서 처방 의약품의 발견, 개발 및 상업화에 주력하는 과학 주도의 글로벌 바이오 제약 회사입니다. & 면역학. 영국 캠브리지에 기반을 둔 AstraZeneca는 100개 이상의 국가에서 사업을 운영하고 있으며 전 세계 수백만 명의 환자가 혁신적인 의약품을 사용하고 있습니다. 방문하시기 바랍니다 스트라제네카.com 소셜 미디어에서 회사를 팔로우하세요. 뿡 빵뀨.
Contacts
투자자 관계 팀에 연락하는 방법에 대한 자세한 내용은 다음을 클릭하십시오. 여기에서 지금 확인해 보세요.. 미디어 연락처의 경우 여기에서 지금 확인해 보세요..
아드리안 켐프
회사 비서
아스트라 제네카 PLC
RNS는 귀하의 IP 주소를 사용하여 약관 준수 여부를 확인하고, 귀하가 이 커뮤니케이션에 포함된 정보를 사용하는 방식을 분석하고, 그러한 분석을 익명으로 다른 사람과 상용 서비스의 일부로 공유할 수 있습니다. RNS와 런던 증권 거래소가 귀하가 제공한 개인 데이터를 사용하는 방법에 대한 자세한 내용은 개인 정보 보호 정책을 참조하십시오.